Moxifloxacin Stada

Moxifloxacin, the active ingredient in Moxifloxacin Stada, is a fluoroquinolone presented as an injection for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and complicated skin and skin structure infections in adult patients.

GNH USA supplies Moxifloxacin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibiotic indicated for several serious bacterial infections.

- Community‑acquired pneumonia: achieves clinical cure and microbiological eradication in adult patients. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute bacterial exacerbations of chronic bronchitis: improves lung function and shortens disease duration. - Complicated skin and skin structure infections: provides bacterial clearance and promotes wound healing.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: self‑limiting loose stools. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: cardiac rhythm changes that may lead to arrhythmia. - Severe hypersensitivity reactions: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile infection: severe colitis following disruption of gut flora.

When using Moxifloxacin, consider the following precautions.

- Renal impairment: adjust therapy based on renal function and monitor. - History of tendon disorders: avoid use or discontinue at first sign of tendon pain. - Cardiac risk: assess QT prolongation risk before initiating. - Concomitant CNS active drugs: monitor for seizures or CNS stimulation. - Pregnancy and lactation: use only if benefits outweigh risks; limited data. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil): increase risk of QT prolongation. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Theophylline: increased plasma levels; monitor for toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of central nervous system stimulation. - Corticosteroids: higher incidence of tendon disorders. - Diuretics (especially thiazides): may potentiate electrolyte disturbances.